sabatolimab

Phase 3Monoclonal antibody

Novartis

sabatolimab is one of 119 small molecule programs targeting Myelofibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisActive, not recruiting

Chronic Myelomonocytic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Chronic Myelomonocytic LeukemiaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Peony

Takeda

Phase 3

6 2

Bicnu

MMelissa K Accordino

Phase 3

1 3

sabatolimab

Novartis

Phase 3

1 4

ALL-Trans Retinoid Acid

UUniversity of Ulm

Phase 3

1 5

Leukine

Sanofi

Preclinical

7 6

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

8 7

Antibiotic

Pfizer

Preclinical

1 8

Daurismo

Pfizer

Preclinical

7 9

Rhtpo

SShandong University

Preclinical

3 10

Chidamide

CChipscreen Biosciences, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Treatment

NCT05201066

Clinical

Trials by Indication[1]

Treatment2 trials

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT05201066·33 enrolled

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Withdrawn· Novartis logo

Novartis·Phase 1/2·NCT05367401

Acute Myeloid Leukemia1 trial

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Terminated· Novartis logo

Novartis·Phase 1/2·NCT04623216·24 enrolled

Chronic Myelomonocytic Leukemia1 trial

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Terminated· Novartis logo

Novartis·Phase 3·NCT04266301·530 enrolled

High Risk1 trial

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Terminated· Novartis logo

Novartis·Phase 2·NCT04812548·20 enrolled

Myelofibrosis1 trial

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated· Novartis logo

Novartis·Phase 1/2·NCT04097821·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for sabatolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sabatolimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sabatolimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Novartis

sabatolimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Treatment2 trials

Acute Myeloid Leukemia1 trial

Chronic Myelomonocytic Leukemia1 trial

High Risk1 trial

Myelofibrosis1 trial

References

Drug Info

Quick Facts

Related News